Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 4, 2008, Pages 229-234

  Gershon, Andrea S ^a,b   Wang, Li ^c   To, Teresa ^a,b   Luo, Jin ^a   Upshur, Ross E G ^a,c  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Beta agonists; Chronic Obstructive Pulmonary Disease; Survival; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; METHYLXANTHINE; TIOTROPIUM BROMIDE;

AGED; ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CAUSE OF DEATH; COHORT STUDIES; CONTINUITY OF PATIENT CARE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; ONTARIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 48749129297     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550802237507     Document Type: Article

References (26)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946.
2. Global Initiative for Chronic Obstructive Pulmonary Disease. Workshop Report, Global Strategy for Diagnosis, Management, and Prevention of COPD. Update Sept. 2005. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute.
3. National Institutes of Health NHLaBI. Morbidity and Mortality: 2004 Chart Book on cardiovascular, lung, and blood diseases. 2004 U.S. Department of Health and Human Services.
4. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82(2):431-443.
5. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (2):CD002876.
6. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004; 11 Suppl B:7B-59B.
7. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007.
8. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1(2):303-312.
9. Canadian Institute of Health Information. Data quality of the discharge abstract database following the first year implementation of ICD-10-CA/CCI - Final report. 2004. Canadian Institute of Health Information.
10. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995; 14(24):2627-2643.
11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775-789.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373-383.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6):613-619.
14. Sin DD, Tu JV. Are elderly patients with obstructive airway disease being prematurely discharged? Am J Respir Crit Care Med 2000; 161(5):1513-1517.
15. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (4):CD003566.
16. PCCF+ Version 4D User's Guide (Geocodes/PCCF). Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files, Including Postal Codes to December 2003. Ottawa: Statistics Canada, 2004.
17. Briggs DD, Jr., Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18(6):397-404.
18. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2007; 2(2):157-167.
19. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21(10):1011-1019.
20. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007; 101(7):1398-1405.
21. Walters E, Gibson P, Lasserson T, Walters J. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007;(1):CD001385.
22. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449-456.
23. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3:CD001104.
24. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297(3):278-285.
25. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005; 162(10):1016-1023.
26. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342(25):1878-1886.